LC
ALXN

Lindbrook Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Lindbrook Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-208
Closed -$38K – 2080
2021
Q2 		$38K Hold
208
– – 0.01% 562
2021
Q1 		$32K Buy
208
+27
+15% +$4.18K 0.01% 586
2020
Q4 		$28K Buy
181
+12
+7% +$1.54K 0.01% 585
2020
Q3 		$19K Buy
169
+10
+6% +$1.08K 0.01% 634
2020
Q2 		$18K Buy
159
+55
+53% +$5.84K 0.01% 655
2020
Q1 		$9K Buy
104
+27
+35% +$2.65K ﹤0.01% 811
2019
Q4 		$8K Sell
77
-92
-54% -$9.84K ﹤0.01% 994
2019
Q3 		$17K Buy
169
+2
+1% +$225 0.01% 768
2019
Q2 		$21K Sell
167
-15
-8% -$1.93K 0.01% 690
2019
Q1 		$24K Sell
182
-4
-2% -$497 0.01% 644
2018
Q4 		$18K Buy
+186
New +$22K 0.01% 658

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return